Compounds > hydroxymethylnitrofurazone

Page last updated: 2024-11-13

hydroxymethylnitrofurazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hydroxymethylnitrofurazone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	85092936
MeSH ID	M0464602

Synonyms (6)

Synonym
hydroxymethylnitrofurazone
5sn29u7jfu ,
518052-13-6
n-(hydroxymethyl)-2-((5-nitro-2-furanyl)methylene)hydrazinecarboxamide
hydrazinecarboxamide, n-(hydroxymethyl)-2-((5-nitro-2-furanyl)methylene)-
nfoh-121

Research Excerpts

Overview

Hydroxymethylnitrofurazone (NFOH) is a trypanocidal prodrug of nitrofurAZone (NF) It has less hepatotoxicity effect than the standard drug benznidazole (BZN)

Excerpt	Reference	Relevance
"Hydroxymethylnitrofurazone (NFOH) is a nitrofurazone prodrug effective in vivo during acute infections, and it has less hepatotoxicity effect than the standard drug benznidazole (BZN) which has been used during short- and long-term treatment. "	( Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: Reduced intensity of tissue parasitism and inflammation-A histopathological study. Chin, CM; da Rosa, JA; de Andrade, CR; Dos Santos, JL; Scarim, CB, 2018)	3.37
"Hydroxymethylnitrofurazone (NFOH) is a trypanocidal prodrug of nitrofurazone (NF), devoid of mutagenic toxicity. "	( Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for Chagas' disease treatment. Chung, MC; Ferreira, EI; Moreno, Ade H; Peccinini, RG; Ribeiro, ML; Serafim, EO; Silva, AT; Vizioli, Ede O, 2013)	2.16
"Hydroxymethylnitrofurazone (NFOH) is a new drug candidate with demonstrated trypanocidal activity; however, its safety is not known."	( Hepatotoxicity in mice of a novel anti-parasite drug candidate hydroxymethylnitrofurazone: a comparison with Benznidazole. Basombrio, MA; Davies, C; Dey, N; Garg, NJ; Negrette, OS; Parada, LA, 2014)	1.36

Pharmacokinetics

Excerpt	Reference	Relevance
" However, the knowledge of pharmacokinetic profile is crucial to evaluate the feasibility of a new drug."	( Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits. Campos, ML; Chin, CM; Davanço, MG; Nogueira Filho, MA; Padilha, EC; Peccinini, RG; Pestana, KC; Pontes Machado, DV, 2013)	0.71
"4) and in human plasma and to determine preclinical pharmacokinetic parameters in rats."	( Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for Chagas' disease treatment. Chung, MC; Ferreira, EI; Moreno, Ade H; Peccinini, RG; Ribeiro, ML; Serafim, EO; Silva, AT; Vizioli, Ede O, 2013)	0.71

Bioavailability

Excerpt	Reference	Relevance
" administration, the oral bioavailability of NF from the administered prodrug was obtained (60."	( Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits. Campos, ML; Chin, CM; Davanço, MG; Nogueira Filho, MA; Padilha, EC; Peccinini, RG; Pestana, KC; Pontes Machado, DV, 2013)	0.71

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (30.77)	29.6817
2010's	8 (61.54)	24.3611
2020's	1 (7.69)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.91 (24.57)
Research Supply Index	2.64 (2.92)
Research Growth Index	4.55 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.91)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	13 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
malic acid malic acid : A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.. 2-hydroxydicarboxylic acid : Any dicarboxylic acid carrying a hydroxy group on the carbon atom at position alpha to the carboxy group.	2.07	1	0	2-hydroxydicarboxylic acid; C4-dicarboxylic acid	food acidity regulator; fundamental metabolite
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	2.07	1	0	cyclitol; hexol
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.1	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	2.79	3	0	C-nitro compound; imidazoles	antitubercular agent
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	2.07	1	0	flavonols; monohydroxyflavone
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	2.79	3	0	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
3-nitrotyrosine 3-nitrotyrosine: RN given refers to parent cpd without isomeric designation. 3-nitrotyrosine : A nitrotyrosine comprising tyrosine having a nitro group at the 3-position on the phenyl ring.	2.1	1	0	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.04	1	0	cyclodextrin
quercetin [no description available]	2.07	1	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
nitrofurazone Nitrofurazone: A topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial WOUNDS AND INJURIES and skin infections. Nitrofurazone has also been administered orally in the treatment of TRYPANOSOMIASIS.. nitrofurazone : A semicarbazone resulting from the formal condensation of semicarbazide with 5-nitrofuraldehyde. A broad spectrum antibacterial drug, although with little activity against Pseudomonas species, it is used as a local application for burns, ulcers, wounds and skin infections.	4.01	13	0
nifurtimox Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.	2.1	1	0	nitrofuran antibiotic

Condition	Indicated	Relationship Strength	Studies	Trials
Leishmania Infection [description not available]	0	2.25	1	0
Leishmaniasis A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).	0	7.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.17	1	0
Innate Inflammatory Response [description not available]	0	2.17	1	0
American Trypanosomiasis [description not available]	0	2.98	4	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	7.17	1	0
Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.	0	2.98	4	0
Acute Liver Injury, Drug-Induced [description not available]	0	2.1	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.1	1	0